Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jul. 31, 2025	Jul. 31, 2024
Cash flows from operating activities:
Net loss	$ (1,742,691)	$ (842,316)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Amortization	0	1,538
Stock-based compensation	108,399	577,805
Gain on sale of product candidates and related assets	0	(16,400,687)
Impairment of investment in preferred stock of Oragenics, Inc.	(0)	12,955,437
Loss from change in fair value of Oragenics, Inc. common stock	459,417	1,638,743
Financing costs paid with issuance of common stock	0	8,750
Allowance for research and development rebate due from Australian government	22,625	0
Amortization of debt discount and closing costs	50,965	330,654
Changes in operating assets and liabilities:
Decrease in prepaid expenses and other current assets	6,990	60,518
Decrease in research and development rebate due from Australian government	0	253,941
Increase (decrease) in accounts payable	228,379	(195,988)
Increase in accrued wages	320,838	246,238
Increase in accrued interest	197,686	150,157
Net cash used in operating activities	(347,392)	(1,215,210)
Cash flows from investing activities:
Cash proceeds from sale of assets	0	1,000,000
Cash proceeds from sale of Oragenics, Inc. common stock, net of commission and fees	69,787	0
Net cash provided by investing activities	69,787	1,000,000
Cash flows from financing activities:
Proceeds from notes payable	300,000	400,000
Principal payments made on notes payable	0	(274,896)
Proceeds from equity financing	0	55,620
Deferred closing costs	(5,690)	0
Net cash provided by financing activities	294,310	180,724
Increase (decrease) in cash	16,705	(34,486)
Cash and cash equivalents:
Beginning of period	2,379	36,865
End of period	19,084	2,379
Supplemental disclosure of cash flow information:
Cash paid for interest	3,864	37,376
Supplemental disclosure of non-cash information:
Warrants issued in connection with debt financing	13,343	28,448
Common stock issued to settle notes payable	0	925,437
Accrued interest paid with common stock	0	68,435
Increase in fees related to extension of LGH debt maturity date recorded as additional principal	0	60,000
Shares issued for exercised warrants	0	3,537
Shares returned	0	100
Deemed dividend for the reduction of exercise price of warrants	0	63,455
Accounts payable assumed by Oragenics	$ 0	$ 325,672